Grover's Disease Treatment Protocols
For Grover's disease (transient acantholytic dermatosis), topical corticosteroids should be used as first-line therapy, with medium- to high-potency formulations applied to affected areas, reserving systemic retinoids (particularly low-dose isotretinoin or acitretin) for refractory cases that fail topical management.
Clinical Overview
Grover's disease typically presents as intensely pruritic papules and vesicle-papules on the trunk of middle-aged to older adults (mean age 59 years), with a male predominance (male-to-female ratio 3.95:1) 1. While 42% of cases resolve spontaneously within one week to eight months 1, many patients require active treatment for symptom control.
Treatment Algorithm
First-Line: Topical Corticosteroids
- Apply medium- to high-potency topical corticosteroids (e.g., triamcinolone, clobetasol, prednicarbate 0.02%) twice daily to affected areas 2, 1
- Use low-potency hydrocortisone on facial areas to avoid skin atrophy 2
- Response rate: 70% 1
- Reassess after 2 weeks; if no improvement, escalate therapy
Adjunctive measures:
- Daily emollients and moisturizers to prevent xerosis
- Oral antihistamines (cetirizine, loratadine, fexofenadine) for pruritus control 3, 2
- Avoid hot showers, excessive soap use, and skin irritants 3
Second-Line: Systemic Retinoids (For Refractory Cases)
When topical therapy fails after 2-4 weeks or disease is extensive:
- Isotretinoin (low-dose): Most commonly reported systemic retinoid for refractory Grover's disease 4
- Acitretin: Alternative systemic retinoid with established efficacy
Important caveat: Systemic retinoids are particularly effective for removing scales and thinning hyperkeratosis 5. They revolutionized treatment of severe acantholytic conditions and represent the most effective systemic option when topical therapy proves insufficient 4.
Third-Line: Systemic Corticosteroids
For severe, recalcitrant disease:
- Oral corticosteroids (prednisone or methylprednisolone)
- Response rate: 64% 1
- Typically reserved for extensive disease or acute flares
- Short-term use recommended due to side effect profile
Alternative/Adjunctive Therapies
For specific clinical scenarios:
- Phototherapy: Can suppress symptoms in select cases 6
- Total skin electron beam radiotherapy: Reported successful in one case of highly refractory disease 7
- Topical tacrolimus: May be considered as steroid-sparing alternative 2
Clinical Pearls and Pitfalls
Key considerations:
- Avoid greasy creams for basic care as they may facilitate folliculitis development 3
- Do not use topical retinoids initially—they may irritate and worsen the condition 3
- Monitor for secondary infection: Impetiginization can occur with staphylococci or streptococci; treat with appropriate antibiotics if present 3
- Consider underlying triggers: Heat, sweating, sun exposure, chemotherapy agents, and even COVID-19 infection have been reported as triggers 8, 9, 10
Disease associations to screen for:
- Cutaneous keratinocyte carcinomas (basal cell carcinoma, squamous cell carcinoma)—GD may mimic multiple skin cancers 11
- Chemotherapy-associated cases require specialized approach based on the specific agent involved 8
- Other dermatoses: eczema, psoriasis, solar keratoses 6
Treatment Escalation Strategy
- Start with high-potency topical corticosteroids + emollients + antihistamines
- Reassess at 2 weeks: If inadequate response, add or switch to systemic retinoids
- For persistent disease at 4-6 weeks: Consider systemic corticosteroids or phototherapy
- For highly refractory cases: Refer to dermatology for consideration of alternative therapies including radiotherapy
The evidence strongly supports topical corticosteroids as the most frequently employed and practical first-line treatment 1, with systemic retinoids providing the highest response rate (86%) for cases requiring escalation 1, 4.